Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD Phase 1 Study of 4ET1103 in Healthy Volunteers
NCT07586514Phase 1Completed
- Sponsor
- 4E Therapeutics
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY4286533 in neuropathic pain (10 cohorts), sponsored by 4E Therapeutics. Primary endpoints: Change from baseline in hematology parameters at 14 days, Change from baseline in serum chemistry parameters at 14 days and 5 more. Started Apr 2025; status: completed.
02
Drugs
LY4286533
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT07586514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586514.